Lurbinectedin

Drug Profile

Lurbinectedin

Alternative Names: PM-01183; PM-1183; Tryptamicidin

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator PharmaMar
  • Developer Fundacion Instituto Valenciano de Oncologia; PharmaMar
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Dioxolanes; Indoles; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer; Small cell lung cancer
  • Phase II Breast cancer; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Phase I Leukaemia

Most Recent Events

  • 01 Jan 2017 PharmaMar completes a phase I trial for Solid tumours (Combination therapy) in United Kingdom and Switzerland (NCT01980667)
  • 22 Dec 2016 Lurbinectedin licensed to Chugai Pharmaceutical in Japan
  • 28 Nov 2016 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top